Trigeminal neuralgia

Zakrzewska, Joanna M; Linskey, M. E.

doi:10.1136/bmj.g474

Cited by 216 publications

(228 citation statements)

References 38 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…Following the data of the published series [1,[27][28][29] (Table 2), the painful attacks are immediately abolished in 80-98% of cases (mean: 92%). A long-term success is reported in 62-89% of cases (mean 77%) at 5-11 years.…”

Section: Resultsmentioning

confidence: 99%

The Surgical Treatment of Trigeminal Neuralgia

Zeme¹

2016

J Pain Relief

View full text Add to dashboard Cite

Trigeminal Neuralgia is a clinical presentation of different diseases, defined in the last edition of the International Classification of Headache Disorders (ICHD-3) as "Classical Trigeminal Neuralgia" and "Painful Trigeminal Neuropathy". In both groups typical and atypical clinical findings are present. They must be taking into consideration for defining a correct clinical diagnosis. In addition MRI findings and other objective signs allow to disclose the Etiology of the Trigeminal Neuralgia. Looking at the Literature reports and at our own experience, techniques, results, and indications of microvascular decompression, radiofrequency thermocoagulation, glycerol rhizolysis, balloon microcompression, and sterotactic radiosurgery of the trigeminal root are reported and discussed.

show abstract

Section: Resultsmentioning

confidence: 99%

The Surgical Treatment of Trigeminal Neuralgia

Zeme¹

2016

J Pain Relief

View full text Add to dashboard Cite

show abstract

“…Oxcarbazepine a prodrug of carbamazepine has been shown to have equal efficacy but with less side effects and better tolerance (18,23,30,39). In a review of 3 RCTs it was found that reduction in attacks were similar with CBZ and oxcarbazepine (40).…”

Section: • Depressionmentioning

confidence: 99%

“…Trigeminal neuralgia continues to be best managed using anticonvulsant drugs, the primary ones being carbamazepine and oxcarbazepine (8,(16)(17)(18)(19)(20)(21)(22)(23). Carbamazepine is the is the first line drug in the management of TN.…”

Section: • Depressionmentioning

confidence: 99%

“…Carbamazepine is the is the first line drug in the management of TN. Several studies and systematic reviews have shown that this is the most effective drug in trigeminal neuralgia.It is considered the gold standard drug in treatment of symptoms of Trigeminal neuralgia (8,16,18,(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30). The advised dosage is 200-1200 mg/day according to the current evidence based guidelines (18,21).…”

Section: • Depressionmentioning

confidence: 99%

“…. The second line therapy is based on very low quality evidence (23). Lamotrigine is an anticonvulsant drug which is used for add on therapy when the first line treatment fails.…”

Section: • Depressionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment Options in Trigeminal Neuralgia an Update

2014

View full text Add to dashboard Cite

show abstract

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects

David

Behrje

Pal

et al. 2018

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

This open‐label, single‐sequence study in healthy subjects investigated the effects of steady‐state carbamazepine on the pharmacokinetic (PK) profile of a single 2‐mg dose of fingolimod. In period 1, a single oral dose of fingolimod 2 mg (day 1) was followed by PK and safety assessments up to 36 days. In period 2, carbamazepine was administered in flexible, up‐titrated doses (600 mg twice daily maximum) for 49 days. Fingolimod was administered on day 35, followed by a study completion evaluation (day 71). The PK analysis included 23 of 26 of the enrolled subjects (88.5%). Coadministration of fingolimod at steady‐state carbamazepine concentrations resulted in increased fingolimod CL/F by 67% through the induction of CYP3A4, a cytochrome with negligible involvement in fingolimod clearance in an uninduced state. Fingolimod Cmax was reduced by 18% and AUCinf by 40%, as was T1/2 (106 vs 163 hours). A similar trend was observed for fingolimod‐P. Models linking fingolimod‐P blood concentrations to lymphocyte count or annual relapse rate suggest that such a decrease would have a low impact on the treatment effect. However, in the absence of efficacy data of fingolimod at doses lower than the therapeutic dose, their coadministration should be used with caution.

show abstract

Trigeminal neuralgia

Cited by 216 publications

References 38 publications

The Surgical Treatment of Trigeminal Neuralgia

The Surgical Treatment of Trigeminal Neuralgia

Treatment Options in Trigeminal Neuralgia an Update

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects

Contact Info

Product

Resources

About